首页> 外文OA文献 >180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

【2h】

180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

机译：180tip Palbociclib，Trastuzumab和内分泌治疗（ET）与METSICIAN的选择（TPC）治疗转移性HER2-阳性和激素受体阳性（HER2 + / HR +）乳腺癌（BC）用PAM50腔内在亚型（Solti-1303 Patricia II）：随机期二期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
E.M. Ciruelos; P. Villagrasa; M. Oliveira; S. Pernas Simon; J. Cortés; S. Vazquez; N. Martínez; A. Perelló; B. Bermejo De Las Heras; E. Martínez; I. Garau Llinas; M. Mele Olive; A. Montaño; E. Vega; B. Cantos; M.J. Echarri; T. Pascual; P. Celiz; X. González-Farré; A. Prat;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Palbociclib与Trastuzumab和内分泌治疗（ET）与医生的选择（TPC）与PAM50腔内在亚型（Solti-1303 Patricia II）的乳腺癌（Solti-1303）的乳腺癌（Solti-1303）：A 多中心，随机，开放标签，第二阶段试验
2. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) [J] . Harbeck Nadia, Gluz Oleg, Christgen Matthias, Journal of Clinical Oncology . 2017,第26期

机译：人表皮生长因子受体2（HER2） - 阳性早期乳腺癌（BC）的脱升升级策略：对西德语研究组的最终分析辅助动态标记调整的个性化治疗试验优化BC HER2早期风险评估和治疗反应预测 - 激素受体阳性期II II型随机试验 - 疗效，安全性和预测标记为12周的Neoadjuvant Trastuzumab Omtansine，或没有内分泌治疗（ET）
3. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. [J] . Inoue K, Nakagami K, Mizutani Breast cancer research and treatment. . 2010,第1期

机译：曲妥珠单抗单药治疗，曲妥珠单抗加多西他赛与曲妥珠单抗加多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗的随机III期试验：JO17360试验组。
4. Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive HER2 negative advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials [O] . Claudia Omarini, Federico Piacentini, Isabella Sperduti, 2020

机译：对于激素受体阳性HER2阴性晚期乳腺癌的老年患者联合内分泌疗法与单独内分泌疗法作为一线治疗：是为患者还是医生开药？ II和III期随机临床试验的荟萃分析
5. ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials [O] . N. Chic, T. Pascual, F. Brasó-Maristany, 2019

机译：ERBB2 mRNA作为HER2阳性（HER2 +）/激素受体阳性（HR +）转移性乳腺癌（BC）的预测因子与HER2封闭与内分泌治疗（ET）组合处理（ET）：对替代品和索尔本米拉试验的回顾性分析

180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

著录项

相似文献

相关主题

期刊订阅